A Phase 2 interventional study of Migalastat HCl and Agalsidase Beta in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 10 sites in 5 countries. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 10th largest by enrollment, is one of 5 that started in 2011, is one of 6 in phase 2, and was the 7th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2011.
This study's enrollment of 20 is close to the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 7 that started in 2011, is one of 6 in phase 2, and was the 7th registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective was to determine the effects of a single dose of migalastat hydrochloride (HCl) (migalastat) 150 and 450 milligrams (mg) on the safety and plasma pharmacokinetics (PK) of agalsidase and the effects of agalsidase on the safety and PK of migalastat 150 mg.
This open-label study was conducted in 2 stages (Stage 1, Stage 2). Stage 1 included migalastat 150 mg; Stage 2 included migalastat 450 mg. Each dose of migalastat was selected to evaluate interaction with each of 3 doses of recombinant agalsidase: 0.5 mg/kilogram (kg) agalsidase beta; 1.0 mg/kg agalsidase beta; 0.2 mg/kg agalsidase alfa.
Migalastat was administered orally. Agalsidase alfa was administered as a 40-minute intravenous (IV) infusion and agalsidase beta was administered as a 2-hour (hr) IV infusion.
Stage 1 consisted of 3 treatment periods with 14 days intervening between each period.
Period 1, Day 1: agalsidase was administered alone.
Period 2, Day 1: migalastat was administered, followed 2 hrs later by agalsidase.
Period 3, Day 7: migalastat was administered alone.
Stage 2 consisted of two 14-day treatment periods in which the plasma exposure of migalastat was characterized when migalastat was administered with agalsidase solely to confirm the attainment of adequate migalastat plasma concentrations.
Period 1, Day 1: agalsidase was administered as an IV infusion using a calibrated infusion pump.
Period 2, Day 1: migalastat was administered, followed 2 hrs later by agalsidase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Migalastat HCl · Biological: Agalsidase Beta
Drug: Migalastat HCl · Biological: Agalsidase Beta
Drug: Migalastat HCl · Biological: Agalsidase Alfa
Drug: Migalastat HCl · Biological: Agalsidase Beta
Drug: Migalastat HCl · Biological: Agalsidase Beta
Drug: Migalastat HCl · Biological: Agalsidase Alfa
Oral capsules, single dose
Also known as: AT1001, Galafold, migalastat
IV infusion, single dose
Also known as: Fabrazyme
IV infusion, single dose
Also known as: Replagal
Change In Area Under The Plasma Concentration Versus Time Curve (AUC) For Active α-Galactosidase A (α-Gal A) Levels After Administration Of Migalastat
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the active α-Gal A enzyme level in plasma using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. The agalsidase plasma PK parameter values for AUC extrapolated from time 0 to infinity (AUCinfinity) and AUC to the last time point at which concentration is quantified (AUC0-t) are reported in hr\*\[nanomoles/hr/milliliter\] (hr\*\[nmol/hr/mL\]). In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
Time frame: 0 hr, 2 hr, 2 days, 7 days, 14 days post dose
Change In Maximum Observed Plasma Concentration (Cmax) For Active α-Gal A Levels After Administration Of Migalastat
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the active α-Gal A enzyme level in plasma using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. The agalsidase plasma PK parameter value for Cmax is reported in nmol/hr/mL. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
Time frame: 0 hr, 2 hr, 2 days, 7 days, 14 days post dose
Change In Time To Maximum Observed Plasma Concentration (Tmax) And Terminal Elimination Half-life (T1/2) For Active α-Gal A Levels After Administration Of Migalastat
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the active α-Gal A enzyme level in plasma using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. The agalsidase plasma PK parameter values for tmax and t1/2 are reported in hr. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
Time frame: 0 hr, 2 hr, 2 days, 7 days, 14 days post dose
Change In AUC For Total α-Gal A Protein Levels After Administration Of Migalastat
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the α-Gal A protein level in plasma by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter value for AUC0-t is reported in hr\*\[nanogram (ng)/hr/mL\]. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
Time frame: 0 hr, 2 hr, 2 days, 7 days, 14 days post dose
Change In Percentage Of AUCinfinity Extrapolated From The Last Time Point At Which Concentration Is Quantified To Infinity (AUCextrapolated %) For Total α-Gal A Protein Levels After Administration Of Migalastat
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the α-Gal A protein level by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter values for AUCextrapolated % are reported. AUCextrapolated % is reported instead of AUCinfinity because small but quantifiable concentrations of α-Gal A protein past 24 hr post-dose extrapolated to infinity comprised \>50% of total AUC in most participants and were unevaluable. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hour after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
Time frame: 0 hr, 2 hr, 2 days, 7 days, 14 days post dose
Change In Cmax For Total α-Gal A Protein Levels After Administration Of Migalastat
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the α-Gal A protein level in plasma by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter values for Cmax is reported in nmol/hr/mL. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
Time frame: 0 hr, 2 hr, 2 days, 7 days, 14 days post dose
Change In Tmax And T1/2 For Total α-Gal A Protein Levels After Administration Of Migalastat
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the total α-Gal A protein level in plasma by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter values for tmax and t1/2 are reported in hr. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
Time frame: 0 hr, 2 hr, 2 days, 7 days, 14 days post dose
Change In AUC For Migalastat After Administration Of Agalsidase
This measure characterized the effects of agalsidase on the plasma PK of migalastat using a validated liquid chromatography-tandem mass spectrometry (LC-MS) assay. The migalastat plasma PK parameter values for AUCinfinity and AUC0-t are reported in hr\*\[ng/hr/mL\]. In Period 2 of Stages 1 and 2, blood samples were collected: just before dosing with migalastat (2 hr prior to the agalsidase infusion) and at 1 hr after migalastat dosing; immediately before the agalsidase infusion and over a 24-hr period after infusion. In Period 3 (Stage 1 only), blood samples were collected before dosing and over the 24-hr period after administration of migalastat.
Time frame: 0 hr, 1 day post dose
Change In Cmax For Migalastat After Administration Of Agalsidase
This measure characterized the effects of agalsidase on the plasma PK of migalastat using a validated liquid LC-MS assay. The migalastat plasma PK parameter values for Cmax are reported in nmol/hr/mL. In Period 2 of Stages 1 and 2, blood samples were collected: just before dosing with migalastat (2 hr prior to the agalsidase infusion) and at 1 hr after migalastat dosing; immediately before the agalsidase infusion and over a 24-hr period after infusion. In Period 3 (Stage 1 only), blood samples were collected before dosing and over the 24-hr period after administration of migalastat.
Time frame: 0 hr, 1 day post dose
Change In Tmax And T1/2 For Migalastat After Administration Of Agalsidase
This measure characterized the effects of agalsidase on the plasma PK of migalastat using a validated LC-MS assay. The migalastat plasma PK parameter values for tmax and t1/2 are reported in hr. In Period 2 of Stages 1 and 2, blood samples were collected: just before dosing with migalastat (2 hr prior to the agalsidase infusion) and at 1 hr after migalastat dosing; immediately before the agalsidase infusion and over a 24-hr period after infusion. In Period 3 (Stage 1 only), blood samples were collected before dosing and over the 24-hr period after administration of migalastat.
Time frame: 0 hr, 1 day post dose
Change From Baseline To Day 7 In Active α-Gal A In Skin Following Treatment With Agalsidase Alone And Co-administration With Migalastat
This measure characterized the effects of agalsidase and migalastat on α-Gal A activity in the skin using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. Baseline was defined as Day 1/Period 1 pre-infusion level. α-Gal A activity is reported in picomoles/mg/hr (pmol/mg/hr). Biopsy samples were obtained: on Day -1/Period 1; 24 hr after initiation of the infusion during Period 1 and Period 2; on Day 7 of Period 1 and Period 2.
Time frame: Baseline, Day 7
| Milestone | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Started | 5 | 3 | 4 | 0 | 0 | 0 |
| Pk population | 5 | 3 | 4 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 5 | 3 | 4 | 0 | 0 | 0 |
| Completed | 5 | 3 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Started | 5 | 3 | 4 | 0 | 0 | 0 |
| Pk population | 5 | 3 | 4 | 0 | 0 | 0 |
| Completed | 5 | 3 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Started | 5 | 3 | 4 | 0 | 0 | 0 |
| Completed | 5 | 3 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 2 | 5 | 4 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 2 | 5 | 4 |
| Pk population | 0 | 0 | 0 | 1 | 5 | 4 |
| Completed | 0 | 0 | 0 | 2 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 1 | 6 | 4 |
| Pk population | 0 | 0 | 0 | 1 | 6 | 4 |
| Completed | 0 | 0 | 0 | 1 | 6 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the active α-Gal A enzyme level in plasma using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. The agalsidase plasma PK parameter values for AUC extrapolated from time 0 to infinity (AUCinfinity) and AUC to the last time point at which concentration is quantified (AUC0-t) are reported in hr\*\[nanomoles/hr/milliliter\] (hr\*\[nmol/hr/mL\]). In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
| hr*[nmol/hr/mL] | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1: AUC0-t | 1132.72 ± 223.215 | 4730.47 ± 1045.068 | 384.20 ± 86.904 | 2409.02 ± NA | 5670.76 ± 3926.295 | 787.23 ± 509.967 |
| Period 2: AUC0-t | 3255.09 ± 904.716 | 9541.21 ± 2813.139 | 1602.58 ± 425.798 | 6127.75 ± NA | 9908.56 ± 3097.746 | 2199.98 ± 875.140 |
| Period 1: AUCinfinity | 1145.73 ± 217.894 | 4871.66 ± 1242.965 | 388.10 ± 83.770 | 2523.87 ± NA | 5851.62 ± 4345.407 | 800.38 ± 509.308 |
| Period 2: AUCinfinity | 3287.09 ± 907.073 | 9765.04 ± 3118.875 | 1626.67 ± 407.595 | 6197.71 ± NA | 10280.79 ± 3399.342 | 2253.95 ± 859.586 |
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the active α-Gal A enzyme level in plasma using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. The agalsidase plasma PK parameter value for Cmax is reported in nmol/hr/mL. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
| nmol/hr/mL | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1:Cmax | 514.18 ± 87.458 | 1682.13 ± 407.862 | 309.02 ± 91.568 | 684.36 ± NA | 1775.12 ± 684.734 | 370.91 ± 113.362 |
| Period 2: Cmax | 899.93 ± 235.701 | 2400.86 ± 928.257 | 515.34 ± 77.207 | 1351.18 ± NA | 2413.31 ± 798.090 | 619.00 ± 141.411 |
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the active α-Gal A enzyme level in plasma using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. The agalsidase plasma PK parameter values for tmax and t1/2 are reported in hr. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
| hr | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1: tmax | 2.07 ± 0.149 | 2.16 ± 0.778 | 0.75 ± 0.170 | 3.00 ± NA | 2.58 ± 0.801 | 0.75 ± 0.170 |
| Period 2: tmax | 2.30 ± 0.447 | 2.41 ± 0.526 | 0.75 ± 0.170 | 3.00 ± NA | 2.58 ± 0.801 | 0.75 ± 0.170 |
| Period 1: t1/2 | 3.91 ± 2.054 | 5.33 ± 4.082 | 4.48 ± 3.132 | 6.50 ± NA | 3.11 ± 1.875 | 5.15 ± 3.645 |
| Period 2: t1/2 | 3.51 ± 1.304 | 4.30 ± 1.712 | 4.27 ± 1.536 | 3.49 ± NA | 4.96 ± 1.532 | 5.31 ± 2.462 |
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the α-Gal A protein level in plasma by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter value for AUC0-t is reported in hr\*\[nanogram (ng)/hr/mL\]. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
| hr*[ng/hr/mL] | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1: AUC0-t | 57187.48 ± 47381.96 | 29905.87 ± 20470.28 | 42256.74 ± 13868.00 | 16229.13 ± NA | 17200.63 ± 16906.97 | 28770.37 ± 10941.44 |
| Period 2: AUC0-t | 56895.40 ± 45753.77 | 34298.23 ± 17022.13 | 42528.55 ± 14652.93 | 16272.03 ± NA | 22031.50 ± 16754.04 | 29816.41 ± 8956.789 |
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the α-Gal A protein level by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter values for AUCextrapolated % are reported. AUCextrapolated % is reported instead of AUCinfinity because small but quantifiable concentrations of α-Gal A protein past 24 hr post-dose extrapolated to infinity comprised \>50% of total AUC in most participants and were unevaluable. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hour after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
| percentage of AUC | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1 | 60.50 ± 22.241 | 27.55 ± 14.642 | 73.26 ± 13.324 | 8.49 ± NA | 12.30 ± 15.307 | 58.37 ± 11.065 |
| Period 2 | 33.97 ± 31.662 | 17.91 ± 11.091 | 54.06 ± 21.538 | 3.25 ± NA | 11.90 ± 13.029 | 47.47 ± 18.832 |
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the α-Gal A protein level in plasma by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter values for Cmax is reported in nmol/hr/mL. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
| nmol/hr/mL | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1: Cmax | 7159.13 ± 4599.113 | 5156.74 ± 2411.601 | 3813.49 ± 1036.627 | 3141.84 ± NA | 3983.05 ± 1422.734 | 3587.46 ± 1181.299 |
| Period 2: Cmax | 7060.29 ± 5016.147 | 5572.63 ± 1915.073 | 4196.18 ± 1264.763 | 2715.38 ± NA | 4170.15 ± 935.512 | 3773.21 ± 950.710 |
This measure characterized the effects of migalastat on the plasma PK of agalsidase by measurement of the total α-Gal A protein level in plasma by Western blot using anti-human Gal A antibody. The agalsidase plasma PK parameter values for tmax and t1/2 are reported in hr. In Period 1 of Stages 1 and 2, blood samples were collected: immediately before the agalsidase infusion and over a 24-hr period after infusion; on Days 2, 7, and 14. In Period 2 of Stages 1 and 2, blood samples were collected: prior to dosing with migalastat (2 hr prior to the agalsidase infusion) and 1 hr after migalastat dosing; immediately before initiation of the agalsidase infusion and over a 24-hr period after initiation of the agalsidase infusion; on Days 2, 7, and 14.
| hr | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1: tmax | 2.07 ± 0.149 | 2.16 ± 0.778 | 0.75 ± 0.170 | 3.00 ± NA | 2.50 ± 0.775 | 0.75 ± 0.170 |
| Period 2: tmax | 2.10 ± 0.548 | 2.24 ± 0.750 | 0.75 ± 0.166 | 3.00 ± NA | 2.50 ± 0.548 | 0.75 ± 0.170 |
| Period 1: t1/2 | 57.78 ± 40.019 | 17.77 ± 8.837 | 86.19 ± 92.048 | 2.96 ± NA | 6.71 ± 7.702 | 30.32 ± 5.010 |
| Period 2: t1/2 | 23.10 ± 22.338 | 9.15 ± 5.621 | 32.95 ± 20.282 | 2.00 ± NA | 5.55 ± 5.553 | 28.05 ± 18.582 |
This measure characterized the effects of agalsidase on the plasma PK of migalastat using a validated liquid chromatography-tandem mass spectrometry (LC-MS) assay. The migalastat plasma PK parameter values for AUCinfinity and AUC0-t are reported in hr\*\[ng/hr/mL\]. In Period 2 of Stages 1 and 2, blood samples were collected: just before dosing with migalastat (2 hr prior to the agalsidase infusion) and at 1 hr after migalastat dosing; immediately before the agalsidase infusion and over a 24-hr period after infusion. In Period 3 (Stage 1 only), blood samples were collected before dosing and over the 24-hr period after administration of migalastat.
| hr*[ng/hr/mL] | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 2: AUC0-t | 15717.87 ± 7140.484 | 9413.79 ± 2153.161 | 16051.81 ± 3441.663 | 49483.00 ± NA | 30450.61 ± 10750.31 | 33920.71 ± 8559.677 |
| Period 3: AUC0-t | 13009.11 ± 3747.086 | 9285.71 ± 2270.875 | 16011.88 ± 5361.097 | NA ± NA | NA ± NA | NA ± NA |
| Period 2: AUCinfinity | 15889.34 ± 7841.968 | 9653.09 ± 2185.031 | 16523.94 ± 3804.018 | 53034.59 ± NA | 31856.37 ± 11283.94 | 34700.89 ± 8429.954 |
| Period 3: AUCinfinity | 13708.03 ± 4278.951 | 9597.10 ± 2253.444 | 16586.14 ± 5818.395 | NA ± NA | NA ± NA | NA ± NA |
This measure characterized the effects of agalsidase on the plasma PK of migalastat using a validated liquid LC-MS assay. The migalastat plasma PK parameter values for Cmax are reported in nmol/hr/mL. In Period 2 of Stages 1 and 2, blood samples were collected: just before dosing with migalastat (2 hr prior to the agalsidase infusion) and at 1 hr after migalastat dosing; immediately before the agalsidase infusion and over a 24-hr period after infusion. In Period 3 (Stage 1 only), blood samples were collected before dosing and over the 24-hr period after administration of migalastat.
| nmol/hr/mL | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 2: Cmax | 1690.00 ± 606.548 | 1295.67 ± 501.654 | 2047.50 ± 192.592 | 4750.00 ± NA | 3763.33 ± 984.574 | 4455.00 ± 1840.697 |
| Period 3: Cmax | 1634.00 ± 396.081 | 1374.00 ± 574.132 | 2035.00 ± 512.803 | NA ± NA | NA ± NA | NA ± NA |
This measure characterized the effects of agalsidase on the plasma PK of migalastat using a validated LC-MS assay. The migalastat plasma PK parameter values for tmax and t1/2 are reported in hr. In Period 2 of Stages 1 and 2, blood samples were collected: just before dosing with migalastat (2 hr prior to the agalsidase infusion) and at 1 hr after migalastat dosing; immediately before the agalsidase infusion and over a 24-hr period after infusion. In Period 3 (Stage 1 only), blood samples were collected before dosing and over the 24-hr period after administration of migalastat.
| hr | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 2: tmax | 3.70 ± 0.651 | 3.33 ± 0.577 | 3.02 ± 0.818 | 4.00 ± NA | 3.33 ± 1.102 | 4.50 ± 1.000 |
| Period 3: tmax | 3.03 ± 0.710 | 3.00 ± 0.000 | 3.03 ± 0.050 | NA ± NA | NA ± NA | NA ± NA |
| Period 2: t1/2 | 5.39 ± 1.098 | 4.95 ± 0.335 | 4.86 ± 0.831 | 6.36 ± NA | 4.87 ± 1.202 | 4.44 ± 1.328 |
| Period 3: t1/2 | 5.31 ± 1.241 | 5.05 ± 0.558 | 4.81 ± 0.601 | NA ± NA | NA ± NA | NA ± NA |
This measure characterized the effects of agalsidase and migalastat on α-Gal A activity in the skin using a qualified assay that measured the rate of enzyme activity using an artificial, fluorescent substrate. Baseline was defined as Day 1/Period 1 pre-infusion level. α-Gal A activity is reported in picomoles/mg/hr (pmol/mg/hr). Biopsy samples were obtained: on Day -1/Period 1; 24 hr after initiation of the infusion during Period 1 and Period 2; on Day 7 of Period 1 and Period 2.
| pmol/mg/hr | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) |
|---|---|---|---|---|---|---|
| Period 1: Day 2 | 334 (-141 to 998) | 857 (795 to 919) | 121 (-52 to 371) | 89 (NA to NA) | 1936 (884 to 3162) | 18 (NA to NA) |
| Period 2: Day 2 | 1508 (221 to 4103) | 2977 (NA to NA) | 437 (35 to 1146) | 647 (NA to NA) | 4019 (1777 to 6168) | 160 (NA to NA) |
| Period 1: Day 7 | 137 (45 to 234) | 553 (315 to 791) | 139 (50 to 229) | 72 (NA to NA) | 613 (252 to 2001) | — |
| Period 2: Day 7 | 574 (-200 to 2588) | 855 (460 to 1250) | 228 (11 to 606) | 235 (NA to NA) | 789 (-174 to 1935) | -100 (NA to NA) |
Collected over Adverse events (AEs) were monitored up to 5.5 months after the first dose of study drug. For Period (Pd) 1 and 2 of Stages 1 and 2, AEs were reported starting 1 day prior (Day -1) to the first dose of study drug (Agalsidase Beta [Agal-B] or Agalsidase Alfa [Agal-A]) to 1 month after the last dose of study drug. For Pd 3 of Stage 1, AEs were reported starting on the day of the first dose of study drug (Day 1) to 1 month after the last dose of study drug (Migalastat [Mig]).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1 Pd 1: 0.5 mg/kg Agal-B (Arm 1) | — | 0/5 (0%) | 4/5 (80%) |
| Stage 1 Pd 2: 150 mg Mig Before 0.5 mg/kg Agal-B (Arm 1) | — | 0/5 (0%) | 0/5 (0%) |
| Stage 1 Pd 3: 150 mg Mig (Arm 1) | — | 0/5 (0%) | 3/5 (60%) |
| Stage 1 Pd 1: 1.0 mg/kg Agal-B (Arm 2) | — | 0/3 (0%) | 3/3 (100%) |
| Stage 1 Pd 2: 150 mg Mig Before 1.0 mg/kg Agal-B (Arm 2) | — | 0/3 (0%) | 2/3 (66.7%) |
| Stage 1 Pd 3: 150 mg Mig (Arm 2) | — | 0/3 (0%) | 0/3 (0%) |
| Stage 1 Pd 1: 0.2 mg/kg Agal-A (Arm 3) | — | 0/4 (0%) | 1/4 (25%) |
| Stage 1 Pd 2: 150 mg Mig Before 0.2 mg/kg Agal-A (Arm 3) | — | 0/4 (0%) | 0/4 (0%) |
| Stage 1 Pd 3: 150 mg Mig (Arm 3) | — | 0/4 (0%) | 2/4 (50%) |
| Stage 2 Pd 1: 0.5 mg/kg Agal-B (Arm 4) | — | 1/2 (50%) | 1/2 (50%) |
| Stage 2 Pd 2: 450 mg Mig Before 0.5 mg/kg Agal-B (Arm 4) | — | 0/1 (0%) | 0/1 (0%) |
| Stage 2 Pd 1: 1.0 mg/kg Agal-B (Arm 5) | — | 0/6 (0%) | 1/6 (16.7%) |
| Stage 2 Pd 2: 450 Mig Before 1.0 mg/kg Agal-B (Arm 5) | — | 0/6 (0%) | 1/6 (16.7%) |
| Stage 2 Pd 1: 0.2 mg/kg Agal-A (Arm 6) | — | 0/4 (0%) | 3/4 (75%) |
| Stage 2 Pd 2: 450 Mig Before 0.2 mg/kg Agal-A (Arm 6) | — | 0/4 (0%) | 4/4 (100%) |
| Event | Stage 1 Pd 1: 0.5 mg/kg Agal-B (Arm 1) | Stage 1 Pd 2: 150 mg Mig Before 0.5 mg/kg Agal-B (Arm 1) | Stage 1 Pd 3: 150 mg Mig (Arm 1) | Stage 1 Pd 1: 1.0 mg/kg Agal-B (Arm 2) | Stage 1 Pd 2: 150 mg Mig Before 1.0 mg/kg Agal-B (Arm 2) | Stage 1 Pd 3: 150 mg Mig (Arm 2) | Stage 1 Pd 1: 0.2 mg/kg Agal-A (Arm 3) | Stage 1 Pd 2: 150 mg Mig Before 0.2 mg/kg Agal-A (Arm 3) | Stage 1 Pd 3: 150 mg Mig (Arm 3) | Stage 2 Pd 1: 0.5 mg/kg Agal-B (Arm 4) | Stage 2 Pd 2: 450 mg Mig Before 0.5 mg/kg Agal-B (Arm 4) | Stage 2 Pd 1: 1.0 mg/kg Agal-B (Arm 5) | Stage 2 Pd 2: 450 Mig Before 1.0 mg/kg Agal-B (Arm 5) | Stage 2 Pd 1: 0.2 mg/kg Agal-A (Arm 6) | Stage 2 Pd 2: 450 Mig Before 0.2 mg/kg Agal-A (Arm 6) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AcroparaesthesiaNervous system disorders | 0/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| Event | Stage 1 Pd 1: 0.5 mg/kg Agal-B (Arm 1) | Stage 1 Pd 2: 150 mg Mig Before 0.5 mg/kg Agal-B (Arm 1) | Stage 1 Pd 3: 150 mg Mig (Arm 1) | Stage 1 Pd 1: 1.0 mg/kg Agal-B (Arm 2) | Stage 1 Pd 2: 150 mg Mig Before 1.0 mg/kg Agal-B (Arm 2) | Stage 1 Pd 3: 150 mg Mig (Arm 2) | Stage 1 Pd 1: 0.2 mg/kg Agal-A (Arm 3) | Stage 1 Pd 2: 150 mg Mig Before 0.2 mg/kg Agal-A (Arm 3) | Stage 1 Pd 3: 150 mg Mig (Arm 3) | Stage 2 Pd 1: 0.5 mg/kg Agal-B (Arm 4) | Stage 2 Pd 2: 450 mg Mig Before 0.5 mg/kg Agal-B (Arm 4) | Stage 2 Pd 1: 1.0 mg/kg Agal-B (Arm 5) | Stage 2 Pd 2: 450 Mig Before 1.0 mg/kg Agal-B (Arm 5) | Stage 2 Pd 1: 0.2 mg/kg Agal-A (Arm 6) | Stage 2 Pd 2: 450 Mig Before 0.2 mg/kg Agal-A (Arm 6) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 1/4 | 0/4 | 0/4 | 1/2 | 0/1 | 1/6 | 0/6 | 0/4 | 0/4 |
| Tinea capitisInfections and infestations | 0/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| Dry skinSkin and subcutaneous tissue disorders | 0/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| LymphoedemaVascular disorders | 0/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| Fabry's diseaseCongenital, familial and genetic disorders | 0/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| Cardiac murmurInvestigations | 2/5 | 0/5 | 0/5 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| Angina pectorisCardiac disorders | 0/5 | 0/5 | 0/5 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| Supraventricular extrasystolesCardiac disorders | 0/5 | 0/5 | 0/5 | 1/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/2 | 0/1 | 0/6 | 0/6 | 0/4 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/2 | 0/1 | 0/6 | 0/6 | 1/4 | 1/4 |
Safety Population: all participants who received at least 1 dose of agalsidase or migalastat. All safety analyses were performed using this set. Participants were analyzed according to treatment received. Three participants from Stage 1 were re-enrolled and newly identified in Stage 2, with 1 receiving both 0.5 and 1.0 mg/kg agalsidase beta.
| Age, Continuous(years) | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) | Total |
|---|---|---|---|---|---|---|---|
| Stage 1 | 50.6 ± 6.88 | 45.7 ± 8.02 | 43.5 ± 5.07 | — | — | — | 47.0 ± 6.84 |
| Stage 2 | — | — | — | 53.5 ± 2.12 | 38.7 ± 12.16 | 38.5 ± 9.15 | 40.1 ± 11.11 |
| Sex: Female, Male(Participants) | Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) | Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) | Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) | Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) | Total |
|---|---|---|---|---|---|---|---|
| Stage 1 — Female | 0 | 0 | 0 | — | — | — | 0 |
| Stage 1 — Male | 5 | 3 | 4 | — | — | — | 12 |
| Stage 2 — Female | — | — | — | 0 | 0 | 0 | 0 |
| Stage 2 — Male | — | — | — | 2 | 6 | 4 | 12 |
Ran from Feb 2011 to primary completion in Oct 2012, 20 months.
Results were first posted in Nov 2018, 6 years after primary completion. A results delay was requested in Jul 2013.
Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat